GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Equity-to-Asset

Mymetics (Mymetics) Equity-to-Asset : -753.75 (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Mymetics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Mymetics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-80.65 Mil. Mymetics's Total Assets for the quarter that ended in Sep. 2023 was $0.11 Mil.

The historical rank and industry rank for Mymetics's Equity-to-Asset or its related term are showing as below:

MYMX' s Equity-to-Asset Range Over the Past 10 Years
Min: -753.75   Med: -6.14   Max: -2.07
Current: -753.75

During the past 13 years, the highest Equity to Asset Ratio of Mymetics was -2.07. The lowest was -753.75. And the median was -6.14.

MYMX's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs MYMX: -753.75

Mymetics Equity-to-Asset Historical Data

The historical data trend for Mymetics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mymetics Equity-to-Asset Chart

Mymetics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.02 -6.49 -6.84 -7.87 -8.87

Mymetics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.57 -8.87 -9.11 -139.80 -753.75

Competitive Comparison of Mymetics's Equity-to-Asset

For the Biotechnology subindustry, Mymetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mymetics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mymetics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Mymetics's Equity-to-Asset falls into.



Mymetics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Mymetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=-68.746/7.755
=-8.86

Mymetics's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=-80.651/0.107
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mymetics  (OTCPK:MYMX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Mymetics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Mymetics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Mymetics (Mymetics) Business Description

Traded in Other Exchanges
N/A
Address
c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066
Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.
Executives
Marcel B. Ruegg director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard officer: President, CEO, CFO ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering director, officer: President and CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin officer: CEO 40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann officer: CSO KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern director 815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin director POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury officer: CSO CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd. 10 percent owner C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd 10 percent owner ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet director, officer: CEO 14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer director, officer: vp corp development
Ernst Lubke director, officer: CFO 39, ROUTE D'ARZIER, ARZIER V8 CH-1273